Haematologic Malignancies
Research activity includes diffuse large B-cell lymphoma, with attention to molecularly defined subgroups, PET/CT response, and circulating tumour DNA as markers used to guide treatment intensity.
- Diffuse large B-cell lymphoma
- ctDNA-guided treatment selection
- Metabolic imaging response
The sponsor also supports studies in testicular germ cell tumours, including seminoma, with interest in adapting radio-chemotherapy to disease extent.
Breast Cancer
Clinical research in early triple-negative breast cancer focuses on neoadjuvant treatment, intratumoral therapy, and combinations with chemoimmunotherapy in the preoperative setting.
- Triple-negative breast cancer
- Neoadjuvant therapy
- Intratumoral treatment approaches
This area reflects an emphasis on locally directed and systemic strategies for aggressive early-stage breast cancer.
Thoracic Oncology
Studies in non-small cell lung cancer address resectable locally advanced disease, combining chemotherapy, radiotherapy, and immunotherapy around surgery.
- Non-small cell lung cancer
- Peri-operative immunotherapy
- Immune-modulatory radiotherapy
The research interest extends to treatment strategies for N2 nodal involvement in surgically managed thoracic cancer.
Genitourinary Cancer
Work in metastatic castration-resistant prostate cancer centers on androgen receptor pathway inhibition alongside standard of care treatment and maintenance approaches.
- Metastatic castration-resistant prostate cancer
- Androgen receptor-targeted therapy
- Maintenance treatment
This area highlights interest in advanced prostate cancer management and disease control in the first-line setting.
